Silencing of CDCA5 inhibits cancer progression and serves as a prognostic biomarker for hepatocellular carcinoma

• DOI: 10.3892/or.2018.6579
• Publication Date: 2018-07-17T10:16:37Z
• Authors: Jianlin Wang; Congcong Xia; Meng Pu; Bin Dai; Xisheng Yang; Runze Shang; Zhen Yang; Ruohan Zhang; Kaishan Tao; Kefeng Dou
• Keywords: Male; 0301 basic medicine; Mice, Inbred BALB C; Carcinoma, Hepatocellular; Cell Cycle; Liver Neoplasms; Mice, Nude; Apoptosis; Cell Cycle Proteins; Articles; Middle Aged; 3. Good health; Gene Expression Regulation, Neoplastic; Mice; 03 medical and health sciences; Cell Movement; Case-Control Studies; Biomarkers, Tumor; Animals; Humans; Female; Adaptor Proteins, Signal Transducing; Cell Proliferation; Follow-Up Studies

Cell division cycle associated 5 (CDCA5) has been with the progression of several types cancers. However, its possible role and mechanism in hepatocellular carcinoma (HCC) remain unknown. In present study, immunohistochemical staining real‑time PCR were used to assess CDCA5 protein mRNA levels clinical samples. Statistical analysis was performed explore correlation between expression clinicopathological features overall survival HCC patients. counting colony formation assays employed analyse effect on cell proliferation, flow cytometry study apoptosis. Moreover, subcutaneous xenograft tumour models implemented predict efficacy targeting vivo. We found that significantly higher tissues, characteristics, predicted poor Silencing small interfering RNA (siRNA) inhibited proliferation induced G2/M arrest vitro. The growth assay revealed downregulation impeded Further indicated depletion decreased ERK1/2 AKT phosphorylation vitro Taken together, these results indicate may act as a novel prognostic biomarker therapeutic target for HCC.